ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

U.S. funds work on two Zika vaccines

by Ann M. Thayer
September 12, 2016 | APPEARED IN VOLUME 94, ISSUE 36

The Biomedical Advanced Research & Development Authority has committed to supporting two companies’ early-stage development of Zika vaccines. Japan’s Takeda Pharmaceutical will receive $20 million over 18 months to complete preclinical work and a Phase I clinical trial of its inactivated whole-virus vaccine. BARDA is also putting $8 million over four years into similar work at Moderna Therapeutics on its mRNA-based vaccine. BARDA may extend the agreements for another five to six years, putting Takeda in a position to receive up to $311 million and Moderna up to $126 million.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment